Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 4—April 2007

Letter

Toxoplasma gondii Prevalence, United States

Suggested citation for this article

To the Editor: We correct the prevalence of Toxoplasma gondii immunoglobulin (Ig) G antibodies published in Emerging Infectious Diseases in 2003 (1). An incorrect cutoff value in the computer program used to calculate seropositivity of anti–T. gondii IgG antibody resulted in some incorrect prevalence rates. We discovered this error when analyzing more recent National Health and Nutrition Examination Survey (NHANES) data.

The cutoff value for anti–T. gondii IgG seropositivity used in the prior publication (1) was >6 IU, which is the correct value for NHANES III 1988–1994 data (2) but not for NHANES 1999–2000 data. Because of a change by the T. gondii test kit manufacturer, the cutoff value for NHANES 1999–2000 seropositivity data was increased to ≥10 IU. This cutoff change from >6 to ≥10 IU does not cause a large difference in the T. gondii seroprevalence reported. In addition, it does not change the overall findings of the article or the overall relationship between NHANES III (1988–1994) and NHANES 1999–2000. However, it does produce a borderline change for 2 demographic subgroups (non-Hispanic white persons and persons born in the United States), for whom the difference from NHANES III to NHANES 1999–2000 data reached statistical significance at p<0.05 in the t test, but the 95% confidence intervals (CIs) for the prevalence estimates for these groups still overlapped between NHANES III and NHANES 1999–2000 (i.e., the t test is a less conservative measure of association than CI).

After this correction, the overall T. gondii antibody prevalence according to NHANES 1999–2000 data changed from 15.8% (95% CI 13.5%–18.1%) to 14.3% (95% CI 12.3%–16.2%). The Table shows the overall and stratified seroprevalence rates for NHANES 1999–2000 (corrected) compared with NHANES III (no corrections needed).

Jeffrey L. Jones*Comments to Author , Deanna Kruszon-Moran†, and Marianna Wilson*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Centers for Disease Control and Prevention, Hyattsville, Maryland, USA;

References

  1. Jones JL, Kruszon-Moran DK, Wilson M. Toxoplasma gondii infection in the United States, 1999–2000. Emerg Infect Dis. 2003;9:13714.PubMed
  2. Jones JL, Kruszon-Moran DK, Wilson M, McQuillan G, Navin T, McAuley JB. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol. 2001;154:35765. DOIPubMed

Table

Suggested citation for this article: Jones JL, Kruszon-Moran D, Wilson M. Toxoplasma gondii prevalence, United States [letter]. Emerg Infect Dis [serial on the Internet]. 2007 Apr [date cited]. Available from http://wwwnc.cdc.gov/eid/article/13/4/06-1355

DOI: 10.3201/eid1304.061355

Related Links

Table of Contents – Volume 13, Number 4—April 2007

Comments to the Authors

Please use the form below to submit correspondence to the authors or contact them at the following address:

Jeffrey L. Jones, Centers for Disease Control and Prevention, Mailstop F22, 4770 Buford Highway, Atlanta, GA 30341, USA;

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Comments to the EID Editors

Please contact the EID Editors via our Contact Form.

TOP